Literature DB >> 10522720

Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy.

R E Jimenez1, A L Warshaw, K Z'graggen, W Hartwig, D Z Taylor, C C Compton, C Fernández-del Castillo.   

Abstract

OBJECTIVE: Pancreatic mucinous cystic neoplasms (MCNs) provide a spectrum of neoplastic changes ranging from benign to malignant. The authors have correlated K-ras mutations and p53 overexpression with the evolution of these tumors.
METHODS: Areas of mild, moderate, or severe dysplasia were microdissected from paraffin-embedded tissue sections of 28 different MCNs (10 benign, 9 borderline, 9 malignant). Nonneoplastic pancreatic ducts were also microdissected from tissues adjacent to the tumors. Ten serous cystadenomas served as negative controls. K-ras codon 12 mutations were identified by a mutant-enriched nested polymerase chain reaction-restriction fragment length polymorphism assay and confirmed by sequencing. p53 overexpression was demonstrated by immunohistochemistry.
RESULTS: K-ras mutations were detected in 20% of benign, 33% of borderline, and 89% of malignant MCNs. Histologically, mutations were found in 26% (7/27) of MCN epithelia with mild dysplasia, 38% (5/13) of MCN epithelia with moderate dysplasia, and 89% (8/9) of MCN epithelia with severe dysplasia or carcinoma. Ten percent (4/39) of nonneoplastic pancreatic ducts at the margins of MCN harbored mutations, all associated with borderline or malignant tumors. Overexpression of p53 occurred in none of the benign or borderline MCNs but in 44% (4/9) of the malignant tumors (p = 0.006 benign/borderline vs. malignant). p53 immunoreactivity was concentrated in areas of severe dysplasia/carcinoma or invasion, where K-ras mutation had been detected.
CONCLUSION: These findings demonstrate a sequential accumulation of genetic changes in the carcinogenesis of MCN. K-ras mutations appear early and increase in proportion with increasing dysplasia. Overexpression of p53 is a late finding observed only in carcinomas, and in combination with mutated K-ras genes. The presence of K-ras mutations in nonneoplastic ducts supports formal pancreatic resection over enucleation for treatment. Mucinous cystic neoplasms may be a useful model to study the evolution of pancreatic ductal adenocarcinomas, in which precursor lesions remain unknown.

Entities:  

Mesh:

Year:  1999        PMID: 10522720      PMCID: PMC1420899          DOI: 10.1097/00000658-199910000-00006

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  47 in total

1.  Cystic neoplasms of the pancreas.

Authors:  D L Kerlin; C F Frey; B I Bodai; P L Twomey; B Ruebner
Journal:  Surg Gynecol Obstet       Date:  1987-12

Review 2.  ras genes.

Authors:  M Barbacid
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

3.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.

Authors:  C A Finlay; P W Hinds; T H Tan; D Eliyahu; M Oren; A J Levine
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

4.  Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma). A clinicopathologic study of 41 cases.

Authors:  J Compagno; J E Oertel
Journal:  Am J Clin Pathol       Date:  1978-06       Impact factor: 2.493

5.  Microcystic adenoma (serous cystadenoma) of the pancreas. A study of 14 cases with immunohistochemical and electron-microscopic correlation.

Authors:  L C Alpert; L D Truong; M I Bossart; H J Spjut
Journal:  Am J Surg Pathol       Date:  1988-04       Impact factor: 6.394

6.  Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis.

Authors:  D M Shin; J Kim; J Y Ro; J Hittelman; J A Roth; W K Hong; W N Hittelman
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

7.  Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice.

Authors:  C J Quaife; C A Pinkert; D M Ornitz; R D Palmiter; R L Brinster
Journal:  Cell       Date:  1987-03-27       Impact factor: 41.582

8.  Cystic neoplasms of the pancreas.

Authors:  K Yamaguchi; M Enjoji
Journal:  Gastroenterology       Date:  1987-06       Impact factor: 22.682

Review 9.  K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.

Authors:  R H Hruban; A D van Mansfeld; G J Offerhaus; D H van Weering; D C Allison; S N Goodman; T W Kensler; K K Bose; J L Cameron; J L Bos
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

10.  K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions.

Authors:  N S Pellegata; F Sessa; B Renault; M Bonato; B E Leone; E Solcia; G N Ranzani
Journal:  Cancer Res       Date:  1994-03-15       Impact factor: 12.701

View more
  40 in total

Review 1.  Cystic lesions in the pancreas: when to watch, when to resect.

Authors:  J H Balcom IV; C Fernandez-Del Castillo; A L Warshaw
Journal:  Curr Gastroenterol Rep       Date:  2000-04

Review 2.  Molecular signatures of pancreatic cancer.

Authors:  Seung-Mo Hong; Jason Y Park; Ralph H Hruban; Michael Goggins
Journal:  Arch Pathol Lab Med       Date:  2011-06       Impact factor: 5.534

Review 3.  Primary cystic neoplasms of the pancreas. Neoplastic disorders of emerging importance-current state-of-the-art and unanswered questions.

Authors:  Michael G Sarr; Michel Murr; Thomas C Smyrk; Charles J Yeo; Carlos Fernandez-del-Castillo; Robert H Hawes; Patrick C Freeny
Journal:  J Gastrointest Surg       Date:  2003 Mar-Apr       Impact factor: 3.452

Review 4.  Molecular mechanism of pancreatic cancer--understanding proliferation, invasion, and metastasis.

Authors:  André L Mihaljevic; Christoph W Michalski; Helmut Friess; Jörg Kleeff
Journal:  Langenbecks Arch Surg       Date:  2010-03-18       Impact factor: 3.445

5.  Promoting effect of a high-fat/high-protein diet in DMBA-induced ductal pancreatic cancer in rats.

Authors:  K Z'graggen; A L Warshaw; J Werner; F Graeme-Cook; R E Jimenez; C Fernández-Del Castillo
Journal:  Ann Surg       Date:  2001-05       Impact factor: 12.969

Review 6.  Novel Biomarkers for Pancreatic Cysts.

Authors:  Harkirat Singh; Kevin McGrath; Aatur D Singhi
Journal:  Dig Dis Sci       Date:  2017-02-14       Impact factor: 3.199

Review 7.  Pathological and molecular evaluation of pancreatic neoplasms.

Authors:  Arvind Rishi; Michael Goggins; Laura D Wood; Ralph H Hruban
Journal:  Semin Oncol       Date:  2014-12-09       Impact factor: 4.929

Review 8.  Insights into the Pathogenesis of Pancreatic Cystic Neoplasms.

Authors:  Vrishketan Sethi; Bhuwan Giri; Ashok Saluja; Vikas Dudeja
Journal:  Dig Dis Sci       Date:  2017-05-12       Impact factor: 3.199

9.  TGF-beta and p53 staining in CT-guided and endoscopic ultrasound fine-needle aspirates of pancreatic adenocarcinoma.

Authors:  Dawn Sears; Richard A Erickson; Lubna Sayage-Rabie; Martha C Escobar
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

Review 10.  Mucinous cystic neoplasms.

Authors:  Carlos Fernández-del Castillo
Journal:  J Gastrointest Surg       Date:  2007-10-23       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.